Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose ...

Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a subgroup of breast cancer patients, but not the overall study population.

HonorHealth Research Institute today announced the opening of its new $7 million Center for Translational Science laboratory in the heart of the Phoenix Bioscience Core (PBC), a 30-acre downtown ...

The Mayo Clinic, a nonprofit healthcare organization focused on research, education and innovation, recently announced a $1.9 billion investment into its Phoenix healthcare campus as part of its ...

City of Hope was the first U.S. institution to offer PIPAC in a clinical ... and Phoenix areas. City of Hope’s affiliated group of organizations includes Translational Genomics Research ...

Get Instant Summarized Text (Gist) An experimental treatment using neoadjuvant triple immunotherapy for glioblastoma, a highly aggressive brain cancer, has shown promising results. This approach ...

Self-described female-founded oncology company Phoenix Molecular Designs ... stages of the study across eight clinical sites across the US. The Dauntless-1 trial aims to extend the impact of ...

NEW YORK – Phoenix Molecular Designs on Thursday said it dosed the first patient in a Phase II clinical trial of the pan-RSK inhibitor PMD-026 as a treatment for patients with hormone receptor ...

A manslaughter trial stemming from the 2023 shooting death of an Internal Revenue Service agent got underway Thursday in Phoenix with opening arguments over whether the death was due to negligence by ...